Biologics, particularly peptide and protein therapies, are a rapidly growing therapeutic area because they can target complex biological pathways with high efficacy. These therapies are becoming important in oncology, metabolic disease, and autoimmune conditions supported by the growing global disease burden and growth in areas such as glucagon-like peptide-1 (GLP-1) and multi-agonist peptides. Injectable biologics are still the standard of care despite challenges in terms of patient burden, adherence, and long-term compliance. This has also led to demand for other delivery routes, especially oral and non-invasive. Progress is being made in molecular engineering, formulation systems, and new delivery routes, such as oral and transdermal approaches, to overcome these barriers.

• Why is the field moving toward integrated, platform-based models that combine molecule optimization and delivery technologies?
• How can an increase in partnerships between pharmaceutical and delivery technology firms pave the way for growth?
• What steps can your team take to achieve growth and focus on patient-centric, scalable solutions for next-generation biologic therapies?